Literature DB >> 21996089

SUVmax during 18FDG-PET scanning in small cell lung cancer: similar information as in non-small cell lung cancer?

C van der Leest1, E F Smit, J Baas, R J Versteijlen, N van Walree, H C Hoogsteden, J G J V Aerts.   

Abstract

In patients with non-small cell lung carcinoma (NSCLC) fluorine-18 fluorodeoxyglucose positron emission tomography (18FDG-PET)-scanning is shown to be of prognostic value. Small cell lung cancer (SCLC) is an aggressive tumor with poor prognosis. Limited results on the prognostic and predictive value of the maximum standard uptake values (SUVmax) obtained during 18FDG-PET scanning in SCLC are available. An observational study in 75 chemonaive patients diagnosed with SCLC who underwent a 18FDG-PET scan was performed. SUVmax values of the primary tumor were related to the overall survival (OS) and the progression free survival (PFS). Significant lower SUVmax values of the primary tumor were observed in patients with stage I-III disease compared to stage IV disease. SUVmax did not discriminate for either OS or PFS in the whole group of patients. In patients with stage IV disease and treatment with chemotherapy, OS and PFS were significantly higher in patients with a high SUVmax. (p-value 0.005 and 0.002 respectively) compared to patients with a low SUVmax value. In patients with SCLC metabolic activity determined using 18FDG-PET (SUVmax) differed between stage I-III and stage IV diseases. Compared to NSCLC, the relationship between SUVmax) and prognosis seems more complex. Copyright Â
© 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21996089     DOI: 10.1016/j.lungcan.2011.09.007

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  6 in total

1.  Prognostic value of fluorine-18 fludeoxyglucose positron emission tomography parameters differs according to primary tumour location in small-cell lung cancer.

Authors:  Tomomi Nobashi; Sho Koyasu; Yuji Nakamoto; Takeshi Kubo; Takayoshi Ishimori; Young H Kim; Akihiko Yoshizawa; Kaori Togashi
Journal:  Br J Radiol       Date:  2016-01-12       Impact factor: 3.039

2.  Circulating U2 small nuclear RNA fragments as a diagnostic and prognostic biomarker in lung cancer patients.

Authors:  Jens Köhler; Martin Schuler; Thomas Christoph Gauler; Stefanie Nöpel-Dünnebacke; Maike Ahrens; Andreas-Claudius Hoffmann; Stefan Kasper; Felix Nensa; Benedikt Gomez; Maria Hahnemann; Frank Breitenbuecher; Danjouma Cheufou; Filiz Özkan; Kaid Darwiche; Mathias Hoiczyk; Henning Reis; Stefan Welter; Wilfried Ernst Erich Eberhardt; Martin Eisenacher; Helmut Teschler; Georgios Stamatis; Wolff Schmiegel; Stephan Albrecht Hahn; Alexander Baraniskin
Journal:  J Cancer Res Clin Oncol       Date:  2015-12-19       Impact factor: 4.553

3.  Prognostic Value of Preradiotherapy (18)F-FDG PET/CT Volumetrics in Limited-Stage Small-Cell Lung Cancer.

Authors:  Leonard T Ong; Mark Dunphy; Amanda Foster; Kaitlin M Woo; Zhigang Zhang; Carmen A Perez; Catherine M Pietanza; Kenneth E Rosenzweig; Daphna Y Gelblum; Andreas Rimner; Abraham J Wu
Journal:  Clin Lung Cancer       Date:  2015-08-03       Impact factor: 4.785

4.  Treatment of malignant pleural effusion in non-small cell lung cancer with VEGF-directed therapy.

Authors:  Zhangqiang Xiang; Xiangyu Deng; Wenfeng He; Qian Yang; Laichao Ni; Marzieh Dehghan Shasaltaneh; Mazaher Maghsoudloo; Gang Yang; Jingbo Wu; Saber Imani; Qinglian Wen
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

5.  Prognostic value of 18F-FDG PET/CT metabolic parameters in small cell lung cancer.

Authors:  Eun Kyoung Choi; Minjae Park; Jooyeon Jamie Im; Yong-An Chung; Jin Kyoung Oh
Journal:  J Int Med Res       Date:  2019-12-27       Impact factor: 1.671

6.  Combining 18F-FDG PET/CT and Serum Lactate Dehydrogenase for Prognostic Evaluation of Small Cell Lung Cancer.

Authors:  Xiaoping Lin; Zizheng Xiao; Yingying Hu; Xu Zhang; Wei Fan
Journal:  Front Pharmacol       Date:  2020-10-28       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.